000170981 001__ 170981
000170981 005__ 20260430151736.0
000170981 0247_ $$2doi$$a10.1007/s13555-026-01737-7
000170981 0248_ $$2sideral$$a149026
000170981 037__ $$aART-2026-149026
000170981 041__ $$aeng
000170981 100__ $$aGómez de la Fuente, Enrique
000170981 245__ $$aReal-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review
000170981 260__ $$c2026
000170981 5060_ $$aAccess copy available to the general public$$fUnrestricted
000170981 5203_ $$aIntroduction. Baricitinib has shown positive results in clinical trials both from efficacy and safety outcomes; however, there is still a need to further understand its use in routine practice in Spain.
Methods. This observational study aimed to describe treatment patterns, persistence, and effectiveness of baricitinib among adult patients with atopic dermatitis (AD) in Spain. A retrospective chart review was carried out in 13 hospitals across Spain. Effectiveness was described using the Eczema Area and Severity Index (EASI), the Investigator’s Global Assessment (IGA), and the Itch and Sleep numerical rating scales (NRS) recorded as part of routine clinical practice. Persistence to treatment was estimated using Kaplan–Meier curves.
Results. Seventy-four patients were included and followed for a mean of 42.1 (standard deviation, SD 21.4) weeks. At baseline, over half of the patients had severe AD, with an EASI > 21 (63%) and an IGA-4 (56.8%). Patients had received a mean of 2.4 (SD 1.2) prior systemic treatments and were prescribed baricitinib mainly due to lack of effectiveness of previous treatment. Most patients were prescribed baricitinib as the sole systemic treatment for AD and did not receive any other systemic treatment during the follow-up. During the study period, 39.2% of patients discontinued baricitinib, mainly due to lack of effectiveness. At week 16, 69.7% of patients who remained on treatment and had a measurement available achieved a ≥ 75% improvement from baseline in the EASI (EASI75) response and 79.3% an IGA score of 0 or 1.
Conclusions. Among patients who remained on treatment, baricitinib showed meaningful clinical improvements in routine clinical practice in Spain. Our findings highlight rapid and sustained clinical improvements, aligning with that observed in other real-world studies
000170981 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttps://creativecommons.org/licenses/by-nc/4.0/deed.es
000170981 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000170981 700__ $$aHerrera, Enrique
000170981 700__ $$aMartinez-Espronceda Esquerdo, Iñigo
000170981 700__ $$aVidal Sarró, David
000170981 700__ $$aFigueras-Nart, Ignasi
000170981 700__ $$aSilvestre Salvador, Juan F.
000170981 700__ $$0(orcid)0000-0001-8034-3617$$aGilaberte, Yolanda$$uUniversidad de Zaragoza
000170981 700__ $$aSantos Alarcón, Sergio
000170981 700__ $$aSerra-Baldrich, Esther
000170981 700__ $$aMunera Campos, Monica
000170981 700__ $$aMoro, Rosa M.
000170981 700__ $$aDíaz-Cerezo, Silvia
000170981 700__ $$aMoyano, Sebastian
000170981 700__ $$aTalavera-Rodríguez, Irene
000170981 700__ $$aNúñez, Mercedes
000170981 7102_ $$11007$$2183$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cÁrea Dermatología
000170981 773__ $$pDermatol. ther.$$tDermatology and therapy$$x2193-8210
000170981 8564_ $$s1414767$$uhttps://zaguan.unizar.es/record/170981/files/texto_completo.pdf$$yVersión publicada
000170981 8564_ $$s2011327$$uhttps://zaguan.unizar.es/record/170981/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000170981 909CO $$ooai:zaguan.unizar.es:170981$$particulos$$pdriver
000170981 951__ $$a2026-04-30-13:58:22
000170981 980__ $$aARTICLE